期刊
FUTURE ONCOLOGY
卷 10, 期 15, 页码 2493-2508出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon.14.162
关键词
biomarker; HIF; prediction; prognosis; renal cancer; sorafenib; sunitinib; VEGF
类别
资金
- National Science Centre OPUS project [UMO-2011/01/B/NZ5/02822]
- Pfizer
- Bayer HealthCare
- Astellas
- GlaxoSmithKline
- Novartis
- Merck
- Vipharm
- Roche
The natural history of clear cell renal cell cancer is highly unpredictable with various progressors and with populations where small renal masses may be accompanied by metastatic disease. Currently, there is a critical need to determine patient risk and optimize treatment regimes. For these patients, molecular markers may offer significant information in terms of prognostic and predictive values, as well as determination of valid therapeutic targets. Until now, only a few of the many identified clear cell renal cell cancer biomarkers have been clinically validated in large cohorts. And only several biomarkers are integrated in predictive or prognostic models. Therefore, a large cohesive effort is required to advance the field of clear cell renal cell cancer prognostic biomarkers through systematic discovery, verification, validation and clinical implementation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据